04/01/2024 Important insight for Castleman disease patients: In a study published in the British Journal of Haematology, members of the Center for Cytokine Storm Treatment & Laboratory (CSTL) at the University of Pennsylvania performed an analysis of blood features from iMCD patients to gain insights into the pathogenesis and clinical characteristics of iMCD. iMCD manifests in three clinical subtypes, iMCD-TAFRO, iMCD-IPL, and iMCD-NOS. In the severe subtype (iMCD-TAFRO), immune reactions may contribute to platelet destruction, whereas in the subtype with high platelet counts (iMCD-IPL), IL-6 appears to stimulate platelet production. These findings open up possibilities for developing personalized therapies that address the specific biological processes underlying each subtype of iMCD.
